

8° WORKSHOP IN EMATOLOGIA TRASLAZIONALE

DELLA SOCIETÀ ITALIANA DI EMATOLOGIA SPERIMENTALE

Firenze - Auditorium CTO - A.O.U. Careggi, 22-23 giugno 2023





**ERK1/2 INHIBITION PREVENTS BONE MARROW FIBROSIS BY REDUCING
PLASMATIC OSTEOPONTIN IN A MYELOFIBROSIS MOUSE MODEL**

Sebastiano Rontauroli, PhD

*Centre for Regenerative Medicine “Stefano Ferrari”, Department of Biomedical, Metabolic and Neural Sciences,
University of Modena and Reggio Emilia, Modena*

Disclosures of Name Surname

Primary Myelofibrosis (PMF)




«bad seeds in bad soil»




KEY POINTS

- Malignant hematopoietic cells create a chronically inflamed microenvironment via secretion of pro-inflammatory cytokines that severely disrupts the normal bone marrow niche.
- The bone marrow niche, particularly stromal cells, can also contribute to chronic inflammation in MPN, perpetuating a disease-permissive environment.
- Specifically targeting stromal inflammation, together with JAK inhibition, is a promising approach to reduce bone marrow fibrosis and treat MPN.

Gleitz et al., CO Hematol, 2021





Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients




Higher SPP1 plasma levels correlate with a more severe fibrosis degree and a shorter OS in PMF patients

ERK1/2 inhibition reduces OPN production by primary CD14+ monocytes in vitro






OPN plasma levels are increased in mice developing BM fibrosis


JAK2 V617F Knock-In mice (Hasan, Blood 2013)





TPO-R agonist treated mice (Maekawa, Leukemia 2017)






ERK1/2 inhibition does not affect thrombocytosis and splenomegaly in MF mice





Ulixertinib constrains OPN production and BM fibrosis in TPO-R agonist treated mice




Combined ERK1/2 and JAK1/2 inhibition does not affect thrombocytosis but improves splenomegaly in MF mice




The combination of Ulixertinib and Ruxolitinib reduces OPN plasma levels and BM fibrosis in MF mice




Treatment with anti-OPN neutralizing antibody recapitulates the antifibrotic effect of Ulixertinib





Untreated



TPO-R agonist + IgG2c




TPO-R agonist + anti-OPN



Conclusions

- OPN is a profibrotic molecule, is increased in PMF patients plasma and correlates to the presence of overt fibrosis.
- Plasmatic OPN is increased also in myelofibrosis mouse models and correlates with the presence of BM fibrosis
- ERK1/2 inhibition reduces OPN production by monocytes in vitro
- ERK1/2 inhibition constrains BM fibrosis development in mice through the reduction of OPN plasma levels.



Acknowledgments



Rossella Manfredini
Elisa Bianchi
Lara Tavernari
Margherita Mirabile

Francesca Pedrazzi
Elena Genovese
Chiara Carretta
Sandra Parenti



A.M. Vannucchi
Paola Guglielmelli
Niccolò Bartalucci
Laura Calabresi
Manjola Balliu



Massimo Dominici
Lorena Losi
Leonardo Potenza
Mario Luppi
Enrico Tagliafico

Massimiliano Dall'Ora
Giulia Grisendi
Luca Fabbiani
Monica Maccaferri

